MVIR Share Price Performance
SEK 1.90
-0.94 (-33.10%)
Price SEK 1.90
Share PriceSEK 1.90
MVIR Community Narratives
There are no narratives available yet.
Recent MVIR News & Updates
No updates
Medivir AB (publ) Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 21, 2025
- Earnings per share (EPS)
- -0.99
- Gross Margin
- -2,318.33%
- Net Profit Margin
- -3,083.62%
- Debt/Equity Ratio
- 0%
Medivir AB (publ) Competitors
About MVIR
- Founded
- 1987
- Employees
- 10
- CEO
- WebsiteView website
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat HDAC inhibitor for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. It has a collaboration and supply agreement with Eisai to evaluate fostrox, a liver-targeted treatment, in combination with lenvatinib for the treatment of liver cancer. The company was incorporated in 1987 and is based in Huddinge, Sweden.
Swedish Market Performance
- 7 Days: -2.2%
- 3 Months: 3.1%
- 1 Year: 3.0%
- Year to Date: -0.9%
Over the last 7 days, the market has dropped 2.9%, driven by losses in every sector, especially the Industrials sector. Overall the market has been flat in the last year. As for the next few years, earnings are expected to grow by 17% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading